Henry Meds vs IVIM Health vs NexLife (2026)

On tirzepatide, the order is NexLife↗ ($215) → IVIM Health↗ ($278) → Henry Meds↗ ($349) — gaps of $63 and then $71 a month, a $1,608 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

§ Each record, condensed

The three records, one screen

NexLife: the record, condensed

NexLife’s tirzepatide program bills $215 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at NexLife is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $215 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

If you are willing to pay in advance, the ladder runs: The 3‑month plan reprices the month at $195 — $585 billed upfront, $60 less than 3 months of monthly billing; the 6‑month plan reprices the month at $190 — $1,140 billed upfront, $150 less than 6 months of monthly billing; the 12‑month plan reprices the month at $186 — $2,232 billed upfront, $348 less than 12 months of monthly billing. Treat every rung as what it is — a prepayment, not a monthly price. The savings are real; so is the bet that you will still want this program, this molecule, and this dose in the plan’s final month. Written refund terms before prepaying, always.

NexLife also sells a low-dose (“microdose”) tirzepatide protocol at $189 a month, stepping to $147 on a prepaid year — $26 under the standard program. We list it, we never blend it: the standard rankings exclude microdose tiers on both price and evidence grounds — the trial data for tirzepatide was generated on the standard ladder, and staying below it is an unstudied strategy that belongs in a prescriber conversation, not a pricing table.

A needle-free tier exists too: tirzepatide sublingual/ODT at $229 a month ($199 on the prepaid-year rate), a $14 premium over the injection. Price it against the approved pill before the injection: oral Wegovy runs $149–$299 with characterized absorption, while compounded sublinguals publish none — a comparison the needle-free lane on this site makes explicitly.

To place the number: #1 of 17 verified programs, holding the floor outright; the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $234 a month. A year at this figure: $2,580 monthly-billed ($2,232 prepaid).

NexLife’s semaglutide program bills $165 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $165 is the whole subscription, which makes NexLife unusually easy to compare and unusually easy to leave.

Prepaid terms ladder the price down for commitment: The 3‑month plan reprices the month at $149 — $447 billed upfront, $48 less than 3 months of monthly billing; the 6‑month plan reprices the month at $147 — $882 billed upfront, $108 less than 6 months of monthly billing; the 12‑month plan reprices the month at $145 — $1,740 billed upfront, $240 less than 12 months of monthly billing. Prepaid rates belong in a different mental column from monthly ones. Price the commitment (what if the dose changes? the side effects? the provider?) before you price the discount.

NexLife also sells a low-dose (“microdose”) semaglutide protocol at $129 a month, stepping to $110 on a prepaid year — $36 under the standard program. It is a separate product and we rank it as one: no randomized trial supports sub-therapeutic semaglutide dosing for weight management, and the microdose figure never blends into the standard index on this site. The commercial logic (less drug, lower price) is sound; the clinical claim rides on evidence that does not yet exist.

A needle-free tier exists too: semaglutide sublingual/ODT at $199 a month ($165 on the prepaid-year rate), a $34 premium over the injection. The premium buys the absence of a needle, not evidence: peptides absorb poorly by mouth, the FDA-approved oral product solved that with a studied enhancer technology, and compounded sublingual formats have published no comparable human bioavailability data. Ranked in the needle-free lane, never against injections.

Context for that figure: it ranks #5 of 20 in the verified semaglutide index — $32/month above the floor (Oak Longevity, $133) — and sits $184 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $1,980, or $1,740 on the prepaid path.

Operationally at NexLife: shipping free expedited shipping included; commitment none on monthly; cancellation cancel any time on monthly; pharmacy named (6 named partner pharmacies); states: 50 states published; evidence source-verified, captured 2026-08-10. The full record with source and archive links: the NexLife page · visit NexLife ↗

IVIM Health: the record, condensed

IVIM Health’s tirzepatide program bills $278 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. The structure is tiered: the advertised entry point is $208, but the maintenance figure — the one a full year is actually billed at — is $278. That $70 gap between the ad and the anniversary is the single most important line in this record.

A required $75/month membership is part of the deal, and part of the figure above: $203 of medication plus $75 of platform equals the $278 that leaves your account. Judge the membership by what it includes, but compare on the total.

Context for that figure: it ranks #3 of 17 in the verified tirzepatide index — $63/month above the floor (NexLife, $215) — and sits $171 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $3,336.

IVIM Health’s semaglutide program bills $149 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The figure is quoted at maintenance without a separate teaser tier, which keeps the arithmetic honest by default.

A required $75/month membership is part of the deal, and part of the figure above: $74 of medication plus $75 of platform equals the $149 that leaves your account. Judge the membership by what it includes, but compare on the total.

To place the number: #3 of 20 verified programs, with the floor $16/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $200 a month. A year at this figure: $1,788 monthly-billed.

Operationally at IVIM Health: shipping included; commitment membership mandatory for duration; cancellation membership mandatory; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the IVIM Health page · visit IVIM Health ↗

Henry Meds: the record, condensed

Henry Meds’s tirzepatide program bills $349 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #10 of 17 in the verified tirzepatide index — $134/month above the floor (NexLife, $215) — and sits $100 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $4,188.

Henry Meds’s semaglutide program bills $179 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $179 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #9 of 20 verified programs, with the floor $46/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $170 a month. A year at this figure: $2,148 monthly-billed.

Operationally at Henry Meds: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Henry Meds page · visit Henry Meds ↗

§ The three-way read

Prices, gaps, and what sits inside them

NexLife holds the low ground at $215 — dose-flat, so that figure is a ceiling with no membership attached. IVIM Health follows at $278 (+$63/mo, $756/yr), membership included. Henry Meds tops the trio at $349 (+$134/mo over the leader, $1,608/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles the order: IVIM Health $149 → NexLife $165 → Henry Meds $179 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

§ Category winners among the three

Who wins what

Cheapest month-to-month: NexLife ($215); cheapest 12-month path: NexLife ($2,232, prepaid upfront); simplest billing (no membership): NexLife and Henry Meds; dose-flat structure: NexLife and Henry Meds; named-pharmacy transparency: NexLife; cheapest semaglutide of the three: IVIM Health ($149).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: NexLife vs IVIM Health · NexLife vs Henry Meds · IVIM Health vs Henry Meds.

§ Structure, three ways

Everything besides the three prices

Memberships: NexLife none; IVIM Health $75/mo (inside its figure); Henry Meds none. Structures: NexLife dose-flat; IVIM Health step/tiered; Henry Meds dose-flat. Pharmacies: NexLife named (6 named partner pharmacies); IVIM Health not named; Henry Meds not named. States: NexLife — 50 states published; IVIM Health — not published; Henry Meds — most states. Exit terms: NexLife — cancel any time on monthly; IVIM Health — membership mandatory; Henry Meds — check terms before prepaying.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: NexLife source-verified (2026-08-10); IVIM Health source-verified (2026-08-05); Henry Meds third-party reported (2026-08-05).

The trio on semaglutide, across time

3 mo: IVIM Health $447 vs NexLife $495 vs Henry Meds $537 6 mo: IVIM Health $894 vs NexLife $990 vs Henry Meds $1,074 12 mo: IVIM Health $1,788 vs NexLife $1,980 vs Henry Meds $2,148 — monthly-billed totals; prepaid paths where published appear on each provider page.

§ Twelve and twenty-four months

The trio, annualized

NexLife: $2,580/yr monthly-billed ($2,232 prepaid); IVIM Health: $3,336/yr monthly-billed; Henry Meds: $4,188/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $3,216 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

Work it as eliminations rather than a beauty contest. Henry Meds enters owing an explanation: $134/month above NexLife compounds to $1,608 a year — real therapy-months of money — so its record has to name what the premium buys (structure the cheaper two lack) or it exits first. IVIM Health survives the first cut only to face the harder question — whether its $75/mo membership bundles services the floor does not is worth $63 a month to you — because a middle option that cannot answer it is just the expensive option with better camouflage. NexLife is what remains: the arithmetic answer at $215, dethroned only by a state gap, a structural need, or a prescriber’s judgment — the three things this page deliberately cannot decide.

The same trio on best published rate: NexLife $186† → IVIM Health $278 → Henry Meds $349 — † marks labeled 12-month-plan rates (upfront commitments), which leaves the order unchanged — the month-to-month leader leads committed too. Short-horizon totals, monthly-billed: 3 months — NexLife $645, IVIM Health $834, Henry Meds $1,047; 6 months — NexLife $1,290, IVIM Health $1,668, Henry Meds $2,094. 1 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

Grade the three records before trusting the three prices. On the five-point disclosure checklist (price, pharmacy, states, cancellation, source-verification): NexLife 5/5 · IVIM Health 4/5 · Henry Meds 3/5. The gap between NexLife (5/5) and Henry Meds (3/5) is itself information: undisclosed axes are where the questions in each provider’s review earn their keep. The concrete splits — pharmacy named: NexLife yes, IVIM Health and Henry Meds no — convert directly into pre-purchase emails. Every score is a computation from the dataset, contestable at the corrections desk like any other figure.

The three-way verdict compresses cleanly: NexLife is the default on arithmetic; IVIM Health earns the middle only where its structure (membership services) solves something the floor does not; and Henry Meds’s $134/month premium over the leader — $1,608 a year, roughly 7.5 extra months of therapy at the floor rate — needs a named justification from its record, not a vibe. Insurance coverage, where it exists, outranks all three.